Search
Prostate Adenocarcinoma Clinical Trials
A listing of 47 Prostate Adenocarcinoma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 47
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Prostate Adenocarcinoma
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
There are currently 47 active clinical trials seeking participants for Prostate Adenocarcinoma research studies. The states with the highest number of trials for Prostate Adenocarcinoma participants are Illinois, California, Pennsylvania and Wisconsin.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial
Recruiting
This phase II randomized control trial assesses the effect of Urolithin A (Uro-A) supplementation compared to placebo in men with biopsy-confirmed prostate cancer undergoing radical prostatectomy (RP) progressive disease. A total of 90 men will be accrued and randomized 1:1 to receive a 1000 mg daily dose of Uro-A in two 250 mg capsules PO BID or two placebo capsules BID daily for 3 to 6 weeks prior to RP. The primary endpoint is to determine the effect of Uro-A on decreasing prostate tumor tiss... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/28/2025
Locations: Cedars Sinai Medical Center, Los Angeles, California +4 locations
Conditions: Prostate Adenocarcinoma
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
Recruiting
This is a single-arm, multicenter open label, international, phase II study of Bipolar Androgen Therapy (BAT) plus Radium-223 (RAD) in men with metastatic castration-resistant prostate cancer (mCRPC). Men with mCRPC with progressive disease (radiographically and/or biochemically) who have been treated with gonadotropin-releasing hormone (GnRH)-analogue (LHRH agonists/antagonists) continuously or bilateral orchidectomy will be enrolled in this study. Previous antiandrogen therapies are permitted,... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Amber Michalik, Baltimore, Maryland +1 locations
Conditions: Prostate Adenocarcinoma, Metastatic Prostate Adenocarcinoma, Castration-resistant
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
Recruiting
This phase II trial investigates the effect of extremely hypofractionated intensity modulated stereotactic body radiotherapy in treating patients with prostate cancer that has rising prostate specific antigen (PSA) after radical prostatectomy. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Hypofracti... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Conditions: Prostate Adenocarcinoma, Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
Recruiting
This phase II trial studies how well prostate specific membrane antigen (PSMA) or fluciclovine positron emission tomography (PET)/computed tomography (CT) site-directed therapy works for treating patients with prostate cancer. PSMA or fluciclovine PET/CT may detect prostate cancer early and may help to show whether patients benefit from site directed treatment to PET detected abnormalities.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania +1 locations
Conditions: Prostate Adenocarcinoma
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
Recruiting
A phase I trial to determine the safety of delivering three sequentially shorter RT schedules (20, 16, and 12 fractions) of HypoFx pelvic nodal RT in combination with a HypoFx, simultaneous integrated boost (SIB) to the prostate that have been designed to incrementally increased the biological equivalent dose (BED) to prostate cancer, while maintaining a constant BED to normal tissue toxicity.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Maryland Proton Treatment Center, Baltimore, Maryland
Conditions: Prostate Cancer, Prostate Adenocarcinoma
PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer
Recruiting
The purpose of this prostate cancer research study is to learn about:
1. Improving control of prostate cancer using radiation therapy, delivered to the para-aortic and pelvic lymph nodes, in addition to systemic androgen suppression therapy;
2. Preserving quality of life after radiation therapy;
3. Leveraging imaging results from prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) scans to evaluate and manage disease progression.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: University of Miami, Miami, Florida
Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer
Recruiting
This phase II trial tests how well risk based de-escalated hormone therapy (i.e., fewer treatments) with radiation works in treating patients with prostate cancer. Androgen deprivation therapy (ADT), such as gonadotropin-releasing hormone analogs (LHRH) and abiraterone acetate (Zytiga), lower the amount of the male hormone, testosterone, made by the body. This may help kill or stop the growth of tumor cells that need testosterone to grow. Radiation therapy uses high energy x-rays, particles, or... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
Recruiting
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/09/2025
Locations: Arkansas Urology, Little Rock, Arkansas +37 locations
Conditions: Prostate Cancer, Prostate Adenocarcinoma
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
Recruiting
Background:
The current standard treatment of prostate cancer is either surgery or radiation. Typically, this includes either the removal or radiation of the whole prostate gland. Many people now seek out focal therapy options to decrease the side effects of treatment. Until now, several forms of physical destruction with heat (thermal ablation), cold (cryotherapy), sound waves (HIFU), laser (FLA), and electrical energy (IRE). A new type of radiation (SBRT) may be an effective way to cure men o... Read More
Gender:
MALE
Ages:
Between 18 years and 120 years
Trial Updated:
06/06/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
Recruiting
This trial studies how well 68Ga-PSMA-11 PET scan works in imaging patients with prostate cancer. Diagnostic procedures, such as 68Ga-PSMA-11 PET may find and diagnose prostate cancer and improve monitoring of treatment response.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
Recruiting
This phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with castration-sensitive prostate cancer that has spread to limited other parts of the body (oligometastatic). Relugolix is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the amount of testosterone (a male hormone) produced by the body. It may stop the growth of cancer cel... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Cancer Center at Saint Joseph's, Phoenix, Arizona +217 locations
Conditions: Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8, Prostate Ductal Adenocarcinoma, Prostate Intraductal Carcinoma
rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance
Recruiting
This clinical trial evaluates whether positron emission tomography-magnetic resonance imaging (PET-MRI) using the radioactive drug radiohybrid prostate-specific membrane antigen (rhPSMA)-7.3 may help in detecting higher grade or stage disease in men with low and favorable intermediate risk prostate cancer who are candidates for active surveillance. A PET scan is a test that uses a radioactive drug and a computer to create images of how organs and tissues in the body are functioning. The radioact... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8
1 - 12 of 47